Skip to main content

Advertisement

Table 2 Clinical trials of CAR-T cells

From: Chimeric antigen receptor T cells: a novel therapy for solid tumors

Target Identifier Institution Phase Status Disease Comments
EGFR NCT02331693 Shanghai Cancer Institute I Recruiting Glioma Autologous T cells transduced with a lentiviral vector
EGFRvIII NCT02844062 Beijing Sanbo Brain Hospital I Recruiting Glioma Lymphodepletion chemotherapy, followed by CAR-T
EGFRvIII NCT01454596 National Cancer Institute (NCI) I/II Recruiting Glioma Autologous T cells, a retroviral vector
EGFRvIII NCT02209376 University of Pennsylvania/University of California I Recruiting Glioma Autologous T cells, a lentiviral vector
EGFRvIII NCT02664363 Duke University Medical Center I Not yet recruiting Glioma Dose escalation cohorts for 4 dose levels
EGFR NCT01869166 Chinese PLA General Hospital I/II Completed NSCLC Safe and feasible
HER2 NCT02713984 Southwest Hospital, China I/II Recruiting HER2-positive cancer  
HER2 NCT01935843 Chinese PLA General Hospital I/II Recruiting HER2-positive cancer  
HER2 NCT02547961 Fuda Cancer Hospital Guangzhou I/II Recruiting Breast cancer A retrovirus vector, preconditioning treatment
HER2 NCT02442297 Baylor College of Medicine I Recruiting Glioma Intracranial injection
HER2 NCT01109095 Baylor College of Medicine I Active, not recruiting Glioma CMV-specific cytotoxic T cells (CMV-T cells)
HER2 NCT00889954 Baylor College of Medicine I Active, not recruiting HER2-positive cancer TGFBeta resistant HER2/EBV-CTLs
HER2 NCT00924287 National Cancer Institute (NCI) I/II Completed HER2-positive sarcoma Results is not encouraging
HER2 NCT00902044 Baylor College of Medicine I/II Completed HER2-positive sarcoma Safe and feasible
MSLN NCT02930993 China Meitan General Hospital I Recruiting Mesothelin-positive tumors Followed lymphodepletion
MSLN NCT02706782 Shanghai Renji Hospital I Recruiting Pancreatic cancer Transcatheter arterial infusion
MSLN NCT02159716 University of Pennsylvania I Active not recruiting Mesothelin-positive tumors Lentiviral transduced
MSLN NCT02792114 Memorial Sloan Kettering Cancer Center I Recruiting Mesothelin-expressing breast cancer Premedicated with acetaminophen and diphenhydramine, and administered cyclophosphamide
MSLN NCT02465983 University of Pennsylvania I Active not recruiting Pancreatic cancer Combination therapy with CART-meso cells and CART19 cells
MSLN NCT02959151 Shanghai Tumor Hospital I/II Recruiting Pancreatic cancer Combined with interventional therapy
MSLN NCT02590747 Chinese PLA General Hospital I Recruiting Mesothelin-positive tumors Retroviral vector-transduced
MSLN NCT01355965 University of Pennsylvania I Completed Pleural mesothelioma Safe and feasible
MSLN NCT02414269 Memorial Sloan Kettering Cancer Center I Recruiting Malignant pleural disease With/without chemotherapy
MSLN NCT01583686 National Cancer Institute (NCI) I/II Recruiting Mesothelin-positive tumors Followed lymphodepletion
MSLN NCT01897415 University of Pennsylvania I Active not recruiting Pancreatic ductal adenocarcinoma (PDA) Transfected with chimeric anti-mesothelin immunoreceptor SS1
IL13Rα2 NCT00730613 City of Hope Medical Center I Completed Glioblastoma Safe and feasible
IL13Rα2 NCT02208362 City of Hope Medical Center I Completed Glioblastoma Safe and feasible
CEA NCT01373047 Roger Williams Medical Center I Completed Liver metastases Safe and feasible
FAP NCT01722149 University of Zurich I Recruiting Malignant pleural mesothelioma Followed lymphodepletion
GD2 NCT00085930 Baylor College of Medicine I Completed Neuroblastoma Safe and feasible
GD2 NCT02107963 National Cancer Institute (NCI) I Completed Sarcoma Osteosarcoma Neuroblastoma Melanoma Safe and feasible
CD133 NCT02541370 Chinese PLA General Hospital I Recruiting CD133-positive malignancies Relapsed and/or chemotherapy refractory advanced malignancies
  1. The details of Table 2 derived from http://clinicaltrials.gov/